Larvol Delta - PEGSN38-A-Phase-2-Study-of-EZN2208-in-Patients-With-Metastatic-Breast-Cancer

firtecan pegol (PEG-SN38) - Belrose

http://clinicaltrials.gov/ct2/show/NCT01036113

Feb 14, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next